Singapore, Jan. 21 -- US-based Pacira BioSciences, Inc. has entered into an agreement with South Korea's LG Chem designed to expand access to opioid-sparing postsurgical pain control for patients in select Asia-Pacific markets.

Through this partnership, LG Chem has the exclusive rights to commercialise EXPAREL(R)(bupivacaine liposome injectable suspension), Pacira's long-acting, local analgesic for postsurgical pain management in the region.

"LG Chem is an established leader in pain management with a proven track record of delivering orthopedic pain solutions to patients across Asia," said Frank D. Lee, chief executive officer of Pacira BioSciences. "By leveraging LG Chem's decades of experience in the orthopedic and surgical markets, w...